Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
JAZZ
STRONG BUYFLAGJazz Pharmaceuticals plc · Healthcare · Ireland · $15.9B · Avg Vol: $200M/d
Jazz Pharmaceuticals has strong momentum at M76 but value at V48 is below the calibrated floor and quality Q53 is modest, so stage one fails. Insider selling of 0.05% is separately adverse.
COMPANY DESCRIPTION
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing innovative medicines for serious diseases, particularly in neuroscience and oncology. It possesses a pipeline of proprietary drugs often addressing unmet medical needs, backed by strong R&D capabilities and a specialized sales force. The company focuses on niche therapeutic areas and uses strategic acquisitions to expand its portfolio, aiming to deliver meaningful innovation to patients.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7B | 3.8B | 4.1B | 4.3B | 5.3% | 4.4B | 4.5B | 4.8B | 6.5% |
| EPS | -3.58 | 6.55 | 9.06 | -5.84 | 38.3% | — | — | — | — |
| Shares | 63.2M | 62.3M | 60.6M | 61.4M | -2.8% | 62.8M | — | — | — |
| Debt | 5.8B | 5.8B | 6.2B | 5.4B | -2.3% | 5.4B | — | — | — |
| Equity | 3.1B | 3.7B | 4.1B | 4.3B | 11.9% | — | — | — | — |
| Op CF | 1.3B | 1.1B | 1.4B | 1.4B | 2.1% | 1.3B | — | — | — |
| Inv CF | -446.2M | -163.1M | -508.2M | -1.5B | — | — | — | — | — |
| Fin CF | -529.5M | -305.3M | 20.5M | -873.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of JAZZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc(you) | $15.9B | 88 | STRONG BUY |
| GHRS | GH Research PLC | $1.9B | 35 | SELL |
| ALKS | Alkermes plc | $8.8B | 78 | BUY |
| PRTA | Prothena Corporation plc | $458M | 28 | SELL |
| ICLR | ICON Public Limited Company | $12.8B | 59 | HOLD |
| MDT | Medtronic plc | $106.5B | 84 | STRONG BUY |
| UPR.IR | Uniphar plc | $1.4B | 71 | BUY |
| PRGO | Perrigo Company plc | $1.4B | 51 | HOLD |
| 0RGI.L | Cosmo Pharmaceuticals N.V. | $1.8B | 16 | STRONG SELL |
| COPN.SW | Cosmo N.V. | $1.4B | 19 | STRONG SELL |
Peer medians: ROE 1.8% · P/E 22.9x · Gross margin 48.5%